Legal Questions Still Dogging Wyeth
"In 2007 alone, Wyeth experienced setbacks with Pristiq, Viviant, Aprela and bifeprunox that reduced or erased the commercial prospects of these assets," Schott explains. The FDA rejected bifeprunox for schizophrenia in August 2007.
In July 2007, the FDA granted conditional approval for Pristiq, a non-hormonal treatment for menopausal symptoms. To gain final approval, Wyeth must conduct a clinical trial to assess potential heart and liver side effects. The trial is expected to take 18 months. In February 2008, the FDA approved Pristiq as a treatment for depression in adults.
In May, the FDA granted conditional approval for Viviant to treat postmenopausal osteoporosis. In December 2007, the FDA gave tentative clearance for Viviant to prevent the disease. Final approval for both uses depends on Wyeth's answering the FDA's questions about risks of stroke and blood clots in leg veins, expected by year-end. Schott figures the FDA will act by mid-2009.
Viviant could come to market in 2010, but Schott says Aprela has greater revenue potential. Aprela, which is still in late-stage clinical trials, combines Premarin and Viviant. Clearly, if the FDA rejects or restricts Viviant, potential sales of Aprela will be affected. Wyeth expects to seek FDA approval for Aprela in the middle of next year.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV